<DOC>
	<DOCNO>NCT00790426</DOCNO>
	<brief_summary>This study evaluate efficacy TKI258 patient advance urothelial cancer</brief_summary>
	<brief_title>Phase II Study TKI258 Advanced Urothelial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<criteria>Patients transitional cell cancer bladder , urethra , ureter , renal pelvis Patients archival tumor tissue available FGFR3 mutational status screen Patients progressive disease Patients measurable disease RECIST Patients previously treat least 1 3 systemic cytotoxic regimen least one regimens include least one following : cisplatin , carboplatin , gemcitabine taxane administer perioperative advanced setting Age ≥ 18 year WHO Performance Status ≤ 2 Patients willing able take oral medication , follow schedule visit , treatment plan laboratory test Patients sign witness informed consent form Patients adequate organ function Patients brain cancer Patients cancer except certain skin , cervical &amp; prostate cancer Patients recover previous cancer treatment Patients severe and/or uncontrolled medical condition could affect participation study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Advanced urothelial cancer</keyword>
</DOC>